Trial
NCT04527887
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Tufts Medical Center
Collaborators
Ocular Therapeutix, Inc.
Condition
Dry Eye
Intervention
Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)
Why stopped
Per sponsor decision due to lengthy enrollment period
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-15